Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: committee papers

Table of Contents

 

01. NICE's response to comments on the Appraisal Consultation Document (ACD)

02. Consultee comments on the ACD - AbbVie

03. Consultee comments on the ACD - British Society of Gastroenterology

04. Consultee comments on the ACD - Crohns & Colitis UK

05. Consultee comments on the ACD - Department of Health

06. Consultee comments on the ACD - Merck Sharpe and Dohme

07. Consultee comments on the executable model - Merck & Sharpe and Dohme

08. Consultee comments on the ACD - Royal College of Nursing

09. Consultee comments on the ACD - Royal College of Physicians

10. Consultee comments on the ACD - Takeda

11. Comments on the ACD - Thanet CCG and South Kent Coast CCG

12. Comments on the ACD - United Kingdom Clinical Pharmacy Association

13. Patient expert comments on the ACD - Cleaver

14. Patient expert comments on the ACD - Singh

15. Public comments on the ACD received via the NICE website

This page was last updated: 11 March 2015